Literature DB >> 21893581

Let the fog be lifted: screening for hepatitis B virus before biological therapy.

Kevin L Winthrop, Leonard H Calabrese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21893581     DOI： 10.1136/annrheumdis-2011-200163

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

Review 1.  Viral hepatitis screening guideline before biological drug use in rheumatic patients.

Authors:  Ömer Karadağ; Timuçin Kaşifoğlu; Birol Özer; Sabahattin Kaymakoğlu; Yeşim Kuş; Murat İnanç; Gökhan Keser; Sedat Kiraz
Journal:  Eur J Rheumatol       Date:  2015-10-28

Review 2.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

3.  The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis.

Authors:  Richard Conway; Michele F Doran; Finbar D O'Shea; Brendan Crowley; Gaye Cunnane
Journal:  Clin Rheumatol       Date:  2014-04-13       Impact factor: 2.980

Review 4.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

5.  Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.

Authors:  Mary Jane Burton; Jeffrey R Curtis; Shuo Yang; Lang Chen; Jasvinder A Singh; Ted R Mikuls; Kevin L Winthrop; John W Baddley
Journal:  Arthritis Res Ther       Date:  2015-05-22       Impact factor: 5.156

Review 6.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

Review 7.  Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Authors:  K L Winthrop; S-H Park; A Gul; M H Cardiel; J J Gomez-Reino; Y Tanaka; K Kwok; T Lukic; E Mortensen; D Ponce de Leon; R Riese; H Valdez
Journal:  Ann Rheum Dis       Date:  2015-08-28       Impact factor: 19.103

8.  Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA.

Authors:  Jingyao Cai; Weimin Wu; Jiali Wu; Zhiyang Chen; Ziwei Wu; Yamei Tang; Min Hu
Journal:  Ann Transl Med       Date:  2022-01

9.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.